Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2003

View Archived Issues

Iptakalim, a novel antihypertensive agent, evaluated in rats and dogs

New data on the molecular mechanisms underlying the antitumor activity of MS-275

Raloxifene reduces likelihood of developing osteoporosis and demonstrates uterine safety

Selective iNOS inhibitors show potential in the treatment of endotoxin-induced uveitis

Fluoratec, a DAT imaging agent in clinical development

NS-2330 clinical program extended to Japan

PharmaCare selected as national distributor for Synagis

Aptamera and Archemix enter development and license agreement for AGRO-100

AVI Biopharma seeks orphan drug designation for AVI-4179 in SARS

Change Technology Partners and Neurologix to merge

Genzyme submits regulatory submission for Hylaform

New phase III trial of loteprednol etabonate for allergic rhinitis

Generex receives SBIR grant for HER-2/neu peptide vaccine for breast cancer

Patent Discovery Corp. acquires ADDE rights

New safety information for salmeterol-based drugs

Nymox reviews pipeline

New topoisomerase inhibitors for use in bacterial or fungal infections and cancer

Dual adenosine A1/A2A receptor antagonists and their use claimed by Fujisawa

Japanese researchers isolate new antiinflammatory and antitumor terpenes from plant roots

Schering-Plough and Pharmacopeia team describes new CXC receptor antagonists

Merck patent covers novel insulin receptor kinase activators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...